Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mapping lifelong chronic health risks for childhood cancer survivors

2.

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

3.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

4.

Coffee, Tea Tied to Lower Risk of Head and Neck Cancer

5.

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot